Related Experiment Video
Updated: May 31, 2025
piggyBac Transposon System Modification of Primary Human T Cells
Published on: November 5, 2012
Efficient production of recombinant human FVII in CHO cells using the piggyBac transposon system
Zhen Yang1, Xueyun Wang2, Shan Luo2
1Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Shenzhen Weiguang Biological Products Co., Ltd., Shenzhen, 518107, PR China; Shenzhen Innovation Pharmaceutical Engineering Laboratory for Recombinant Plasma Proteins, Shenzhen, 518107, PR China.
Abstract:
As an important coagulation factor, activated coagulation factor VII (FVIIa) is mainly used to treat the bleeding of hemophilia patients who have developed inhibitory antibodies against FVIII and FIX conventional treatment. Recombinant human factor VII (rhFVII) produced in mammalian cell lines have been developed as the most important resource of FVIIa. However, cell lines express rhFVII protein derived from an exogenous expression vector at a lower level than most other proteins. In the current study, we have shown efficient rhFVII production in CHO cell lines using piggyBac (PB) transposon system. rhFVII is successfully expressed in fed-batch culture of CHO cells, and the expression of rhFVII up to 100 mg/L. Moreover, the purified secreted rhFVII was determined by SDS-PAGE and Western Blot. The coagulation activity was determined by the chromogenic Activity ELISA kit. In conclusion, this study has demonstrated that the piggyBac transposon system can be used for an efficient production of recombinant FVII.
